These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 25544378)

  • 1. Modulating the serotonin system in the treatment of major depressive disorder.
    Morrissette DA; Stahl SM
    CNS Spectr; 2014 Dec; 19 Suppl 1():57-67; quiz 54-7, 68. PubMed ID: 25544378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
    Pehrson AL; Sanchez C
    Drug Des Devel Ther; 2015; 9():603-24. PubMed ID: 25653499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function.
    Dale E; Pehrson AL; Jeyarajah T; Li Y; Leiser SC; Smagin G; Olsen CK; Sanchez C
    CNS Spectr; 2016 Apr; 21(2):143-61. PubMed ID: 26346726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The under-recognized role of dopamine in the treatment of major depressive disorder.
    Montgomery SA
    Int Clin Psychopharmacol; 2008 Mar; 23(2):63-9. PubMed ID: 18301120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
    Sanchez C; Asin KE; Artigas F
    Pharmacol Ther; 2015 Jan; 145():43-57. PubMed ID: 25016186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons.
    Vadodaria KC; Ji Y; Skime M; Paquola A; Nelson T; Hall-Flavin D; Fredlender C; Heard KJ; Deng Y; Le AT; Dave S; Fung L; Li X; Marchetto MC; Weinshilboum R; Gage FH
    Mol Psychiatry; 2019 Jun; 24(6):795-807. PubMed ID: 30700803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.
    Bymaster FP; McNamara RK; Tran PV
    Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.
    Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC
    Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.
    Verkhratsky A; Parpura V; Scuderi C; Li B
    Adv Neurobiol; 2021; 26():317-347. PubMed ID: 34888840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Fornaro M; Fiengo ALC; Martinotti G; Vellante F; Matarazzo I; Vecchiotti R; Perna G; Di Nicola M; Carano A; Di Bartolomeis A; De Giannantonio M; De Berardis D
    CNS Neurol Disord Drug Targets; 2017; 16(1):65-92. PubMed ID: 27781949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major depressive disorder and diabetes: does serotonin bridge the gap?
    De Long NE; Stepita RA; Taylor VH; Holloway AC
    Curr Diabetes Rev; 2015; 11(2):71-8. PubMed ID: 25705990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.
    Sagud M; Nikolac Perkovic M; Vuksan-Cusa B; Maravic A; Svob Strac D; Mihaljevic Peles A; Zivkovic M; Kusevic Z; Pivac N
    Psychopharmacology (Berl); 2016 Sep; 233(17):3259-67. PubMed ID: 27356518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression.
    Taciak PP; Lysenko N; Mazurek AP
    Pharmacol Rep; 2018 Feb; 70(1):37-46. PubMed ID: 29309998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
    Sahli ZT; Banerjee P; Tarazi FI
    Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.